Precigen Announces FDA Confirmation that the Ongoing Phase I/II Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval

By
Laurisa Dohm
-
0
221
The FDA also confirmed no additional randomized, placebo-controlled trial will be required to support submission of a biologics license application.
[Precigen Inc.]
Press Release